These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 34000287)
1. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade. Tseng YJ; Lee CH; Chen WY; Yang JL; Tzeng HT J Invest Dermatol; 2021 Nov; 141(11):2690-2698.e6. PubMed ID: 34000287 [TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1. Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T Front Immunol; 2024; 15():1365894. PubMed ID: 38779680 [TBL] [Abstract][Full Text] [Related]
3. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH Front Immunol; 2021; 12():654463. PubMed ID: 34054817 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Liu N; Zhang J; Yin M; Liu H; Zhang X; Li J; Yan B; Guo Y; Zhou J; Tao J; Hu S; Chen X; Peng C Mol Ther; 2021 Jul; 29(7):2321-2334. PubMed ID: 33744468 [TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
6. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259 [TBL] [Abstract][Full Text] [Related]
7. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915 [TBL] [Abstract][Full Text] [Related]
8. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049 [No Abstract] [Full Text] [Related]
9. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655 [TBL] [Abstract][Full Text] [Related]
10. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Setordzi P; Chang X; Liu Z; Wu Y; Zuo D Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617 [TBL] [Abstract][Full Text] [Related]
11. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Wang Z; Wu X Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727 [TBL] [Abstract][Full Text] [Related]
12. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551 [TBL] [Abstract][Full Text] [Related]
13. Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model. El Meskini R; Atkinson D; Kulaga A; Abdelmaksoud A; Gumprecht M; Pate N; Hayes S; Oberst M; Kaplan IM; Raber P; Van Dyke T; Sharan SK; Hollingsworth R; Day CP; Merlino G; Weaver Ohler Z Mol Cancer Res; 2021 Aug; 19(8):1422-1436. PubMed ID: 33888600 [TBL] [Abstract][Full Text] [Related]
14. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S Front Immunol; 2021; 12():619209. PubMed ID: 33790893 [TBL] [Abstract][Full Text] [Related]
15. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. Lu L; Risch E; Halaban R; Zhen P; Bacchiocchi A; Risch HA Int Immunopharmacol; 2023 May; 118():110092. PubMed ID: 37004344 [TBL] [Abstract][Full Text] [Related]
16. Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549 [TBL] [Abstract][Full Text] [Related]
17. PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. Wu B; Sun X; Yuan B; Ge F; Gupta HB; Chiang HC; Li J; Hu Y; Curiel TJ; Li R Int J Biol Sci; 2020; 16(9):1526-1535. PubMed ID: 32226299 [TBL] [Abstract][Full Text] [Related]
18. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422 [TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Yan Y; Zhang L; Zuo Y; Qian H; Liu C Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750 [TBL] [Abstract][Full Text] [Related]
20. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis. Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]